Kintor Pharmaceutical Limited (Kintor Pharma) filed its Monthly Return for Equity Issuer for the period ended 30 June 2026, confirming a stable capital structure and full compliance with Hong Kong listing regulations.

Authorised Capital • Total authorised share capital held steady at 700.00 million ordinary shares with a par value of USD 0.0001 each, equivalent to USD 70,000. • No changes were recorded in the authorised or registered share capital during the month.

Issued Shares and Treasury Position • Issued shares remained unchanged at 498.66 million; the company held no treasury shares. • With no share issues, cancellations, or repurchases, total issued share capital was unchanged at 498.66 million shares. • Approximately 201.34 million authorised shares are still unissued, providing future headroom within the existing mandate.

Public Float Compliance • Kintor Pharma confirmed adherence to the Main Board’s minimum 25% public float requirement as of 30 June 2026.

Corporate Governance Confirmation • The filing, signed by Chairman, Executive Director and CEO Youzhi Tong, states that all necessary authorisations and regulatory obligations related to any securities activities have been satisfied. • No outstanding share options, warrants, convertibles, or other equity-linked instruments were reported for the month.

The absence of share movements underscores a period of capital stability for Kintor Pharma, while the company maintains full compliance with Hong Kong Exchange listing rules.